Therefore, this study aimed to evaluate whether CTCs, cCSCs and peripheral lymphocytes with/without PD-1 expression were associated with prognosis and therapy response among patients who were receiving palliative chemotherapy for initially unresectable, recurrent/metastatic HNSCC. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.